Deng Jie, Zhou Zhi, Zhou Duo, Huang Renliang, Guo Min, Zhou Qiaomiao
Department of Genetics and Prenatal Diagnosis, Hainan Women and Children's Medical Center, Haikou, Hainan 570206, China.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2024 Dec 10;41(12):1483-1490. doi: 10.3760/cma.j.cn511374-20240902-00466.
To investigate the results of preimplantation genetic testing for monogenic diseases (PGT-M) in a Chinese pedigree affected with Primary carnitine deficiency (PCD).
A pedigree affected with PCD who visited Hainan Women and Children's Medical Center in April 2023 due to "SLC22A5 gene mutation found in offspring genetic testing and preparing for a second child" was selected as the study subject. Pathogenicity of the proband's variant sites was determined by referring to the Standards and Guidelines for the Interpretation of Sequence Variants established by the American College of Medical Genetics and Genomics (ACMG). Sanger sequencing was used to verify the variant sites of SLC22A5 gene in the proband and her parents, and the single nucleotide polymorphism (SNP) haplotype of the family was constructed by SNP microarray (SNP array) method to determine the carrier status of pathogenic genes. After fertilization via assisted reproductive technology, whole genome amplification (WGA) was performed on the biopsied trophoblastic cells. Sanger sequencing, next-generation sequencing (NGS), and SNP array techniques were then used to detect the variants in the SLC22A5 gene and chromosome copy number variation (CNV) in the embryos. Embryos without the variants were selected for transferring. After the successful pregnancy of the proband's mother, amniocentesis was not performed for prenatal diagnosis due to repeated vaginal bleeding. After delivery, neonatal peripheral blood sample was collected to verify the results of PGT-M, and follow-up was conducted. This study was reviewed and approved by the Medical Ethics Committee of Hainan Women and Children's Medical Center (Ethics No. HNWCMC-2022-178).
In this study, the c.338G>A and c.760C>T variants in SLC22A5 gene were evaluated as pathogenic variants. Sanger sequencing results of this family showed that the c.338G>A and c.760C>T variants of the proband were inherited from his father and mother, respectively. Haplotypes of c.338G>A and c.760C>T variants of SLC22A5 gene were successfully constructed. PGT-M results showed that 2 of the 8 blastulas biopsied failed WGA, and the CNV detection results of the remaining 6 blastocysts were all euploid: 2 had no mutations in the SLC22A5 gene, 3 were single heterozygous carriers of paternal or maternal origin, and 1 was compound heterozygous carriers of paternal and maternal origin. Combined with the embryo morphology score, an intrauterine singleton pregnancy was achieved after the successful transfer of an optimal embryo with no CNV abnormalities and no paternal or maternal SLC22A5 gene mutations, resulting in the birth of a healthy female baby at 38 weeks of gestation. The results of peripheral blood chromosomal karyotyping analysis, CNV detection and SLC22A5 gene c.338G>A and c.760C>T site variant detection of the infant were consistent with those of PGT-M, and no abnormality was found.
PGT-M had helped the couple carrying SLC22A5 gene variant to have a healthy offspring and effectively blocked the transmission of PCD in this family.
探讨在中国一个患有原发性肉碱缺乏症(PCD)的家系中进行单基因病植入前基因检测(PGT-M)的结果。
选取一个因“子代基因检测发现SLC22A5基因突变,准备生育二胎”于2023年4月就诊于海南妇女儿童医学中心的PCD家系作为研究对象。参照美国医学遗传学与基因组学学会(ACMG)制定的《序列变异解读标准与指南》确定先证者变异位点的致病性。采用Sanger测序法验证先证者及其父母SLC22A5基因的变异位点,并通过单核苷酸多态性(SNP)微阵列(SNP阵列)法构建该家系的SNP单倍型,以确定致病基因的携带状态。经辅助生殖技术受精后,对活检的滋养层细胞进行全基因组扩增(WGA)。然后采用Sanger测序、二代测序(NGS)和SNP阵列技术检测胚胎中SLC22A5基因的变异及染色体拷贝数变异(CNV)。选择无变异的胚胎进行移植。先证者母亲成功妊娠后,因反复阴道流血未行羊膜腔穿刺术进行产前诊断。分娩后,采集新生儿外周血样本验证PGT-M结果,并进行随访。本研究经海南妇女儿童医学中心医学伦理委员会审核批准(伦理编号:HNWCMC-2022-178)。
本研究中,SLC22A5基因的c.338G>A和c.760C>T变异被评估为致病变异。该家系的Sanger测序结果显示,先证者的c.338G>A和c.760C>T变异分别遗传自其父亲和母亲。成功构建了SLC22A5基因c.338G>A和c.760C>T变异的单倍型。PGT-M结果显示,活检的8个囊胚中有2个WGA失败,其余6个囊胚的CNV检测结果均为整倍体:2个SLC22A5基因无突变,3个为父源或母源单杂合携带者,1个为父源和母源复合杂合携带者。结合胚胎形态学评分,成功移植1个无CNV异常且无父源或母源SLC22A5基因突变的优质胚胎后获得宫内单胎妊娠,妊娠38周时分娩出一名健康女婴。婴儿外周血染色体核型分析、CNV检测及SLC22A5基因c.338G>A和c.760C>T位点变异检测结果与PGT-M结果一致,未发现异常。
PGT-M帮助携带SLC22A5基因变异的夫妇生育了一个健康后代,并有效阻断了该家系中PCD的传递。